Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CPA1 | P15085 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286031 | 1.00 | MEN1 (0.63) | MEN1KMT2AL3MBTL1CA1CA2 | |
| Chloroform SCHEMBL28104113 | 0.95 | MEN1 (0.59) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL7297540 | 0.86 | MMP2 (0.65) | CA1CA2NAALAD2MMP2MMP9 | |
| SCHEMBL7297543 | 0.86 | MMP2 (0.65) | CA1CA2NAALAD2MMP2MMP9 | |
| SCHEMBL17318156 | 0.85 | L3MBTL1 (0.62) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL17318080 | 0.85 | L3MBTL1 (0.62) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL3266667 | 0.84 | MEN1 (0.60) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL28396545 | 0.84 | L3MBTL1 (0.64) | MEN1KMT2AL3MBTL1CA1CA2 | |
| SCHEMBL8912956 | 0.81 | L3MBTL1 (0.78) | MEN1KMT2AL3MBTL1MMP2MMP9 | |
| SCHEMBL17111996 | 0.81 | ITGB3 (0.49) | MEN1KMT2AL3MBTL1CA2MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 303 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081362-A | Preparation method and application of plant sulfo small peptide PSK based on synthetic biology | — | 2026-05-26 | — | — | CN | claimed |
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | VERSEAU THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | claimed |
| EP-4679086-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| EP-4634233-A2 | CHECKPOINT MODULATORS FOR ENHANCING IMMUNOTHERAPY | Dana-Farber Cancer Institute, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-12435327-B2 | Genetically encoded tyrosine sulfation of proteins in eukaryotes | TRUSTEES OF BOSTON COLLEGE (MA) | 2025-10-07 | — | — | US | claimed |
| US-20250215063-A1 | CD4 MUTEINS AND METHODS OF USING THE SAME | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2025-07-03 | — | — | US | claimed |
| US-20250195327-A1 | METHOD FOR PREVENTING OR LIMITING PROGRESSION OF MYOPIA | CATALTHEIA GROUP, INC. (US) | 2025-06-19 | — | — | US | claimed |
| US-12252527-B2 | CD4 muteins and methods of using the same | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-03-18 | — | — | US | claimed |
| US-20240344040-A1 | PROKARYOTIC AND EUKARYOTIC CELLS WITH BIOSYNTHESIZED SULFOTYROSINE FOR GENETIC INCORPORATION | WILLIAM MARSH RICE UNIVERSITY (US) | 2024-10-17 | — | — | US | claimed |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | GENENTECH INC (US) | 2024-07-25 | — | — | US | claimed |
| EP-3980463-A1 | ANTI-PSGL-1 COMPOSITIONS AND METHODS FOR MODULATING MYELOID CELL INFLAMMATORY PHENOTYPES AND USES THEREOF | Verseau Therapeutics, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114026427-A | Marker for diagnosing renal disease and diagnostic method | 深圳市中医院 | 2022-02-08 | — | — | CN | claimed |
| US-20210294125-A1 | SOFT CONTACT LENS | BF RESEARCH S.R.L. (IT) | 2021-09-23 | — | — | US | claimed |
| EP-3797333-A1 | SOFT CONTACT LENS | BF Research S.r.L. (IT) | 2021-03-31 | — | — | EP | claimed |
| EP-3383883-A1 | SALTS OF CONJUGATES FOR CANCER THERAPY | BioSight Ltd. (IL) | 2018-10-10 | — | — | EP | claimed |
| WO-2017094011-A1 | SALTS OF CONJUGATES FOR CANCER THERAPY | BIOSIGHT LTD. (IL) | 2017-06-08 | — | — | WO | claimed |
| EP-1411964-A4 | PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF | OREGON HEALTH SCIENCE UNIVERSI (US) | 2006-06-14 | — | — | EP | claimed |
| US-20040248807-A1 | Peptides which modulate blood coagulation and methods of use thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-09 | — | — | US | claimed |
| EP-1411964-A2 | PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF | OREGON HEALTH SCIENCE UNIVERSITY (US) | 2004-04-28 | — | — | EP | claimed |
| WO-2003003988-A2 | PEPTIDES WHICH MODULATE BLOOD COAGULATION AND METHODS OF USE THEREOF | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2003-01-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552873-B2 | Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | CD209, CSF3R, CHI3L1 | MEN1 3559/4885KMT2A 1593/4885L3MBTL1 720/4885 |
| US-20240247034-A1 | CYSTINE KNOT SCAFFOLD PLATFORM | LRP6, LDLR, KDR | MEN1 4072/4885KMT2A 2288/4885L3MBTL1 2280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.